In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of this etiology. We aimed to assess the in vitr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/7/1784 |
| _version_ | 1827733760211156992 |
|---|---|
| author | Małgorzata Brauncajs Filip Bielec Anna Macieja Dorota Pastuszak-Lewandoska |
| author_facet | Małgorzata Brauncajs Filip Bielec Anna Macieja Dorota Pastuszak-Lewandoska |
| author_sort | Małgorzata Brauncajs |
| collection | DOAJ |
| description | Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of this etiology. We aimed to assess the in vitro effectiveness of eravacycline to carbapenemase-producing Gram-negative bacilli clinical isolates identified in hospitals in Łódź, Poland. We analyzed 102 strains producing KPC, MBL, OXA-48, GES, and other carbapenemases. Eravacycline susceptibility was determined following the EUCAST guidelines. The highest susceptibility was found in KPC (73%) and MBL (59%) strains. Our results confirmed in vitro the efficacy of this drug against carbapenem-resistant strains. However, eravacycline has been indicated only for treating complicated intra-abdominal infections, significantly limiting its use. This aspect should be further explored to expand the indications for using eravacycline supported by evidence-based medicine. Eravacycline is one of the drugs that could play a role in reducing the spread of multidrug-resistant microorganisms. |
| first_indexed | 2024-03-11T01:16:37Z |
| format | Article |
| id | doaj.art-62513bf33b994282976e061d5eb54a24 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T01:16:37Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-62513bf33b994282976e061d5eb54a242023-11-18T18:24:55ZengMDPI AGBiomedicines2227-90592023-06-01117178410.3390/biomedicines11071784In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central PolandMałgorzata Brauncajs0Filip Bielec1Anna Macieja2Dorota Pastuszak-Lewandoska3Department of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, 90-151 Lodz, PolandDepartment of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, 90-151 Lodz, PolandDepartment of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, 90-151 Lodz, PolandDepartment of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, 90-151 Lodz, PolandEravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of this etiology. We aimed to assess the in vitro effectiveness of eravacycline to carbapenemase-producing Gram-negative bacilli clinical isolates identified in hospitals in Łódź, Poland. We analyzed 102 strains producing KPC, MBL, OXA-48, GES, and other carbapenemases. Eravacycline susceptibility was determined following the EUCAST guidelines. The highest susceptibility was found in KPC (73%) and MBL (59%) strains. Our results confirmed in vitro the efficacy of this drug against carbapenem-resistant strains. However, eravacycline has been indicated only for treating complicated intra-abdominal infections, significantly limiting its use. This aspect should be further explored to expand the indications for using eravacycline supported by evidence-based medicine. Eravacycline is one of the drugs that could play a role in reducing the spread of multidrug-resistant microorganisms.https://www.mdpi.com/2227-9059/11/7/1784eravacyclineantimicrobial susceptibilityGram-negative rodscarbapenem resistance |
| spellingShingle | Małgorzata Brauncajs Filip Bielec Anna Macieja Dorota Pastuszak-Lewandoska In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland Biomedicines eravacycline antimicrobial susceptibility Gram-negative rods carbapenem resistance |
| title | In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland |
| title_full | In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland |
| title_fullStr | In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland |
| title_full_unstemmed | In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland |
| title_short | In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland |
| title_sort | in vitro activity of eravacycline against carbapenemase producing gram negative bacilli clinical isolates in central poland |
| topic | eravacycline antimicrobial susceptibility Gram-negative rods carbapenem resistance |
| url | https://www.mdpi.com/2227-9059/11/7/1784 |
| work_keys_str_mv | AT małgorzatabrauncajs invitroactivityoferavacyclineagainstcarbapenemaseproducinggramnegativebacilliclinicalisolatesincentralpoland AT filipbielec invitroactivityoferavacyclineagainstcarbapenemaseproducinggramnegativebacilliclinicalisolatesincentralpoland AT annamacieja invitroactivityoferavacyclineagainstcarbapenemaseproducinggramnegativebacilliclinicalisolatesincentralpoland AT dorotapastuszaklewandoska invitroactivityoferavacyclineagainstcarbapenemaseproducinggramnegativebacilliclinicalisolatesincentralpoland |